The main aim of this study is to learn about the time between the start and stop of treatment with brigatinib in Chinese participants with non-small-cell lung cancer (NSCLC) and who have been positively diagnosed with having the anaplastic lymphoma kinase (ALK) gene. Other study aims are to learn about the progression of NSCLC and participants' response to treatment with brigatinib.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria
1. Age ≥ 18 years.
2. Participant with histologically/cytologically confirmed locally advanced or metastatic NSCLC.
3. Participants with ALK gene rearrangement confirmed by local hospital medical records.
4. Participants who received brigatinib since September 1, 2022 as first line treatment confirmed by medical records.
5. Participants who have at least one medical record after the start of brigatinib treatment.
Exclusion Criteria
1. Participants participated in NSCLC-related interventional clinical trials after locally advanced or metastatic NSCLC diagnosis and during brigatinib treatment.
2. Previously received any other TKIs, including ALK-targeted TKIs.
3. Previously received more than 1 regimen of systemic anticancer therapy for locally advanced or metastatic disease.
4. Participants have been diagnosed as malignancies (excluding completely resected basal cell carcinoma, bladder carcinoma in situ, cervical carcinoma in situ) in addition to NSCLC within the past 5 years.
Primary outcome measure(s)
Real-World Time-to-Treatment Discontinuation (rwTDD) — Up to 8 years rwTTD is defined as the time from initiation of brigatinib to discontinuation of treatment for any reason, including disease progression, death, serious adverse events, or participant preference.
Trial sites (1)
Facility
City
Region
Status
Department of Oncology, Shanghai pulmonary hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.